Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Circio Holding ASA's revenue for the
six
months ended in Dec. 2025 was kr0.00 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was kr0.00 Mil.
Circio Holding ASA's Revenue per Share for the
six
months ended in Dec. 2025 was kr0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was kr0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Circio Holding ASA's highest 3-Year average Revenue per Share Growth Rate was 230.70% per year. The lowest was -57.30% per year. And the median was -53.80% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Circio Holding ASA Revenue Related Terms
Circio Holding ASA Revenue Historical Data
* Premium members only.
The historical data trend for Circio Holding ASA's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Circio Holding ASA's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Circio Holding ASA Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Circio Holding ASA's Revenue distribution charts can be found below:
* The bar in red indicates where Circio Holding ASA's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Circio Holding ASA (LTS:0RIS) has a Revenue of kr0.00 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Circio Holding ASA and its competitors.
Is Circio Holding ASA's Revenue too high?
Circio Holding ASA's current Revenue is kr0.00 Mil. Overall, Circio Holding ASA has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Circio Holding ASA's Revenue compare to VRTX and REGN?
Circio Holding ASA's Revenue of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Circio Holding ASA and its competitors. Circio Holding ASA's current Revenue is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Circio Holding ASA stock overvalued right now?
Circio Holding ASA (LTS:0RIS) has a current Revenue of kr0.00 Mil. The current Revenue is kr0.00 Mil. Circio Holding ASA's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Circio Holding ASA (LTS:0RIS), the current Revenue is kr0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Circio Holding ASA is a biotechnology company developing circular RNA expression technology for gene and cell therapy applications. It has developed a circular RNA (circRNA) vector expression platform known as circVec, which is based on modular genetic constructs designed for circRNA production within target cells. The platform is being developed for applications including genetic medicine, cell therapy, and chronic disease treatment. The company's activities also include the development of RNA, DNA, and viral therapeutic technologies related to gene expression and protein production.
25GF Score
Get the complete analysis for LTS:0RIS
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RIS has been successfully added to your 
